EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.7.1.171 | Diabetic Nephropathies |
23492569 |
Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality. |
therapeutic application
unassigned |
1
0 |
| 2.7.1.171 | Hyperglycemia |
32467223 |
Role of fructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complications in patients with T2DM. |
unassigned |
0 |
| 2.7.1.171 | Lung Neoplasms |
31420355 |
Deglycation of NRF2 by FN3K Promotes Oncogenesis and Drug Resistance. |
ongoing research
unassigned |
1
0 |
| 2.7.1.171 | Lung Neoplasms |
34437174 |
Deglycation of NRF2 by FN3K Promotes Oncogenesis and Drug Resistance. |
ongoing research
unassigned |
1
0 |
| 2.7.1.171 | Macular Degeneration |
32899850 |
Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration. |
therapeutic application
unassigned |
4
0 |
| 2.7.1.171 | Neoplasms |
21253391 |
Low red blood cell levels of deglycating enzymes in colorectal cancer patients. |
diagnostic usage
ongoing research
unassigned |
4
4
0 |
| 2.7.1.171 | Neoplasms |
21319141 |
Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. |
therapeutic application
unassigned |
1
0 |
| 2.7.1.171 | Neoplasms |
33466626 |
The Taming of Nuclear Factor Erythroid-2-Related Factor-2 (Nrf2) Deglycation by Fructosamine-3-Kinase (FN3K)-Inhibitors-A Novel Strategy to Combat Cancers. |
causal interaction
ongoing research
therapeutic application
unassigned |
4
2
1
0 |
| 2.7.1.171 | protein-fructosamine 3-kinase deficiency |
20009024 |
Effects of fructosamine-3-kinase deficiency on function and survival of mouse pancreatic islets after prolonged culture in high glucose or ribose concentrations. |
causal interaction
ongoing research
unassigned |
1
2
0 |
